American Society for Clinical Oncology (400K PDF)
A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.
May 2009
Thomas Wiesel Partners Healthcare Conference (4.8MB PDF)
Executive overview of Alder Biopharmaceuticals, including clinical programs and attributes of Alder's antibody production system.
September 2009
Lazard Capital Management Healthcare Conference (5.3MB PDF)
Executive overview of Alder Biopharmaceuticals, including clinical programs and attributes of Alder's antibody production system.
November 2009
A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.
May 2009
Thomas Wiesel Partners Healthcare Conference (4.8MB PDF)
Executive overview of Alder Biopharmaceuticals, including clinical programs and attributes of Alder's antibody production system.
September 2009
Lazard Capital Management Healthcare Conference (5.3MB PDF)
Executive overview of Alder Biopharmaceuticals, including clinical programs and attributes of Alder's antibody production system.
November 2009
